男女羞羞视频在线观看,国产精品黄色免费,麻豆91在线视频,美女被羞羞免费软件下载,国产的一级片,亚洲熟色妇,天天操夜夜摸,一区二区三区在线电影
Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Study finds virus antibodies last at least 12 months

By WANG XIAOYU | CHINA DAILY | Updated: 2021-07-08 09:27
Share
Share - WeChat
A recovering pneumonia patient gives a thumbs-up to medical workers at Wuhan University's Zhongnan Hospital, in early 2020. [GAO XIANG/FOR CHINA DAILY]

Antibodies against the novel coronavirus can last for at least 12 months in more than 70 percent of recovered COVID-19 patients, a study published by Chinese researchers on Tuesday shows.

The finding adds to growing evidence that vaccination, which elicits an immune response in a way similar to how a live virus triggers human bodies to generate antibodies, can "effectively restrict the spread of SARS-CoV-2", the study said.

The study, published online by Nature Communications, was conducted by China National Biotech Group, a Sinopharm subsidiary, and the National Research Center for Translational Medicine at Shanghai Jiao Tong University.

Researchers collected 1,782 convalescent plasma samples from 869 recovered COVID-19 patients in Wuhan, Hubei province, within 12 months of diagnosis, and tested them for the presence and amount of RBDIgG, a type of antibody that indicates the strength of immunity against the virus.

Testing results showed that in nine months, levels of the antibody dropped to 64.3 percent of the initial level when they contracted the virus, and then stabilized into the 12th month.

"It shows that once immune responses against the novel coronavirus are induced in human bodies, antibody levels can be maintained for quite a long time," China National Biotech Group said in an article on its WeChat account on Wednesday.

The study found that the antibody response was significantly stronger in male participants than in their female counterparts in the early stages of infection, but the difference dwindled over time and nearly disappeared in 12 months.

Among participants aged 18 to 55, the older ones developed higher antibody levels, it added.

The company said the study is the longest-running research aimed at examining the persistence of antibody response in recovered COVID-19 patients.

The finding was published as mass vaccination in China proceeds smoothly, with the country stepping up vaccine donations or sales overseas.

As of Tuesday, about 1.3 billion doses of vaccines had been administered nationwide, the National Health Commission said on Wednesday.

China National Biotech Group added that the study will help improve understanding of the immunological memory elicited by the virus, and provide guidance on future research into vaccine-induced immunity and future vaccination policies in China and abroad.

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 屏南县| 贞丰县| 宜川县| 义乌市| 上林县| 囊谦县| 灵台县| 炎陵县| 阿坝| 临泉县| 二连浩特市| 衡阳市| 如皋市| 巴林右旗| 庆安县| 望城县| 北流市| 右玉县| 达拉特旗| 二连浩特市| 南丰县| 福建省| 丰原市| 武乡县| 靖边县| 昌邑市| 依兰县| 札达县| 浦东新区| 马边| 梨树县| 扶余县| 永清县| 舒兰市| 辽宁省| 闸北区| 西城区| 永和县| 彭阳县| 乐亭县| 济源市| 云和县| 余庆县| 北京市| 竹山县| 鄂州市| 三台县| 肃北| 香河县| 涞源县| 滦平县| 白城市| 浮梁县| 南靖县| 丰县| 冕宁县| 华安县| 曲沃县| 赤水市| 仙桃市| 陵水| 大姚县| 余江县| 工布江达县| 团风县| 拉萨市| 拉萨市| 涪陵区| 三原县| 镇安县| 类乌齐县| 隆子县| 吉首市| 昌邑市| 巩留县| 光山县| 枞阳县| 福贡县| 肇东市| 日照市| 沙洋县| 西贡区|